BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts (Q37056708)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Daniel S Peeper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Christian U Blank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Kristel Kemper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Oscar Krijgsman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Xiangjun Kong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Paulien Cornelissen-Steijger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Aida Shahrabi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fleur Weeber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Daphne L van der Velden

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Onno B Bleijerveld

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Thomas Kuilman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Roel J C Kluin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Chong Sun

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Emile E Voest

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

David J Adams

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

John B Haanen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

16 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

263-277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

14 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Genomic Classification of Cutaneous Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

CopywriteR: DNA copy number detection from off-target sequence data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Improved overall survival in melanoma with combined dabrafenib and trametinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

What do, can and should we learn from models to evaluate potential anticancer agents?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Mutations of the BRAF gene in human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Identification of BRAF 3'UTR Isoforms in Melanoma.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

Towards a unified model of RAF inhibitor resistance

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4929150

An in vivo platform for translational drug development in pancreatic cancer

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27320919

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CELREP.2016.05.064

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

27320919

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27320919%20AND%20SRC:MED&resulttype=core&format=json